ALX Oncology announces upcoming presentation of Phase 2 trial data on evorpacept as a biomarker in HER2+ gastric cancer.
Quiver AI Summary
ALX Oncology Holdings Inc. announced that it will present updated data from its Phase 2 ASPEN-06 trial at the Society for Immunotherapy of Cancer's 40th Annual Meeting, taking place in November 2025. The trial evaluates evorpacept, the company's leading therapeutic candidate, used in combination with HERCEPTIN®, CYRAMZA®, and paclitaxel for treating patients with HER2-positive advanced gastric cancer. The presentation will focus on CD47 overexpression as a predictive biomarker for the response to evorpacept. The ASPEN-06 trial enrolled 127 patients and aims to assess the effectiveness of this novel therapy in those who have previously undergone treatments that included HER2-directed therapy and chemotherapy. ALX Oncology continues to develop innovative cancer therapies, with evorpacept being a key component of its ongoing research.
Potential Positives
- Company will present updated data from the Phase 2 ASPEN-06 trial at a major oncology conference, highlighting potential advancements in HER2-positive gastric cancer treatment.
- Data presentation focuses on CD47 overexpression as a key predictive biomarker for the response to the lead candidate, evorpacept, which could enhance its therapeutic positioning.
- ALX Oncology's lead candidate, evorpacept, demonstrates potential to serve as a cornerstone therapy in immuno-oncology, showcasing innovation in the pipeline.
Potential Negatives
- Details on the efficacy and safety of evorpacept in the Phase 2 trial are not provided, leaving uncertainty about the treatment's effectiveness.
- The press release includes a cautionary note about substantial risks and uncertainties related to forward-looking statements, which may undermine investor confidence.
- The reliance on future data presentation at a conference means current stakeholders do not have immediate evidence of progress or success in the clinical trial, potentially impacting stock performance.
FAQ
What is the purpose of the ASPEN-06 trial?
The ASPEN-06 trial evaluates the efficacy of evorpacept combined with other treatments for HER2-positive gastric cancer.
When will the updated data from ASPEN-06 be presented?
The updated data will be presented on November 8, 2025, at the SITC Annual Meeting.
Who is the lead author of the upcoming presentation?
The lead author is Zev A. Wainberg, M.D., Co-Director of the GI Oncology Program at UCLA.
What is evorpacept's role in cancer treatment?
Evorpacept is positioned as a potential cornerstone therapy in the evolving field of immuno-oncology.
How many patients were enrolled in the Phase 2 portion of ASPEN-06?
127 adult patients were enrolled in the Phase 2 portion of the ASPEN-06 trial.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALXO Insider Trading Activity
$ALXO insiders have traded $ALXO stock on the open market 7 times in the past 6 months. Of those trades, 3 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ALXO stock by insiders over the last 6 months:
- JASON LETTMANN (CHIEF EXECUTIVE OFFICER) has made 2 purchases buying 92,233 shares for an estimated $99,352 and 1 sale selling 2,382 shares for an estimated $1,525.
- HARISH SHANTHARAM (Chief Financial Officer) purchased 75,000 shares for an estimated $58,402
- SHELLY PINTO (SVP, FINANCE AND CAO) has made 0 purchases and 3 sales selling 4,154 shares for an estimated $1,955.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALXO Hedge Fund Activity
We have seen 19 institutional investors add shares of $ALXO stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,597,503 shares (-69.0%) from their portfolio in Q2 2025, for an estimated $663,123
- ALMITAS CAPITAL LLC added 1,185,214 shares (+87.6%) to their portfolio in Q2 2025, for an estimated $491,982
- STATE STREET CORP removed 594,621 shares (-82.7%) from their portfolio in Q2 2025, for an estimated $246,827
- MPM BIOIMPACT LLC removed 550,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $228,305
- GEODE CAPITAL MANAGEMENT, LLC removed 455,486 shares (-59.1%) from their portfolio in Q2 2025, for an estimated $189,072
- MILLENNIUM MANAGEMENT LLC removed 451,470 shares (-47.8%) from their portfolio in Q2 2025, for an estimated $187,405
- BANK OF AMERICA CORP /DE/ removed 416,651 shares (-28.7%) from their portfolio in Q2 2025, for an estimated $172,951
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALXO Analyst Ratings
Wall Street analysts have issued reports on $ALXO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/21/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/09/2025
To track analyst ratings and price targets for $ALXO, check out Quiver Quantitative's $ALXO forecast page.
$ALXO Price Targets
Multiple analysts have issued price targets for $ALXO recently. We have seen 2 analysts offer price targets for $ALXO in the last 6 months, with a median target of $1.5.
Here are some recent targets:
- Colin Bristow from UBS set a target price of $1.0 on 05/21/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $2.0 on 05/09/2025
Full Release
-
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland. The Phase 2 trial evaluated evorpacept, the Company’s lead therapeutic candidate, in combination with HERCEPTIN ® (trastuzumab), CYRAMZA ® (ramucirumab) and paclitaxel, for patients with previously treated HER2-positive advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer.
Details for the poster presentation at SITC 2025 are as follows:
Title:
CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial
First Author:
Zev A. Wainberg, M.D., Professor of Medicine and Co-Director of GI Oncology Program, University of California, Los Angeles
Abstract:
496
Date and Time:
Saturday, November 8, 2025, 10:00 a.m. – 6:35 p.m. ET
Location:
Poster Hall (Exhibit Halls AB)
About ASPEN-06
ASPEN-06 is a randomized Phase 2 (open-label)/3 (blinded), international, multi-center study, evaluating evorpacept in combination with HERCEPTIN ® (trastuzumab), CYRAMZA ® (ramucirumab) and paclitaxel, for patients with metastatic second- or third-line HER2 overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy. One hundred twenty-seven adult patients were enrolled in the Phase 2 portion of the study.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and entered the clinic in a Phase 1 trial in August 2025. More information is available at www.alxoncology.com and on LinkedIn @ ALX Oncology .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objectives of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
[email protected]
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
[email protected]
(917) 519-9577
